Also Read: Covid- 19 Vaccine To Be Ready In One Month: Donald Trump
The initiating step towards its journey in India was the establishment of the Radiation Medicine Centre (RMC) in 1963 by Dr. Homi Jehangir Bhabha, the ‘Father of the Indian Nuclear Programme.’ Since then, the specialty has grown by leaps and bounds in both the public and the private sector. Government institutions such as the PGIMER, Chandigarh, AIIMS, Radiation Medicine Centre, Tata Memorial Hospital and SGPGI, Lucknow are the centres of excellence having state-of-the-art facilities and the most advanced training courses in Nuclear Medicine in India. The private sector is a major player in delivering Nuclear Medicine facilities to the Indian populace and includes several corporate hospitals as well as stand-alone centres. The facilities in these centres, including diagnostic testing and therapies, parallels those in the best centres in the United States and the European Union, and even outperforms them in several areas. A combined approach of academics, research and clinical training has ensured that the Nuclear Medicine trainees are well at par with their global counterparts. The same is witnessed in international conferences, symposia, and is evident by the Indian contribution to the leading international journals of Nuclear Medicine.
Also Read: Serum Institute of India Gets DCGI's Green Signal To Resume Phase 2-3 Trials For Oxford-AstraZeneca Covid-19 Vaccine
However, the significant geographical disparity in the availability of Nuclear Medicine procedures in India needs attention, by the policymakers, the healthcare industry leaders, and certainly, by the common man in coercing their elected representatives. The practice of Nuclear Medicine is largely focussed on tier-1 and some major tier-2 cities. Most state-owned medical colleges are yet to start a functioning nuclear medicine department. Again, the number of Nuclear Medicine facilities in the tier-1 and tier-2 cities are limited, leading to a major deficit in the facility: patient ratio. Nuclear medicine departments at government institutions, such as PGIMER remain overburdened and experience huge inflow of the patients, almost always exceeding the facility capacity. The limited permeation of this technology across the country is mostly due to the high setup and maintenance costs, limited availability of skilled manpower and a constant requirement of radioisotopes. The medical cyclotrons are required to provide 18F-FDG, a common radioisotope used in the PET facilities for diagnosis of several cancers and in other non-cancerous conditions. A total of 19 operational cyclotrons and 222 PET/CT facilities were on record in India in the year 2018, for a population of 1.3 billion. The need of the hour is to focus our attention on improving the accessibility of the Nuclear Medicine facilities across the country. The policymakers need to provide exclusive funding to the government institutions for development and functioning of the Nuclear Medicine facilities and incentivize the private players in helping extend its availability. We can also count on international collaborations that would eventually help the facilities in India. In this regard, India -Russia collaboration for the supply of clinically useful radioisotopes and especially the therapeutic radiopharmaceuticals holds a great potential. This kind of initiation at the governmental levels (DAE) between the two countries can help availability, affordability and accessibility of the emerging radiotheranostics to the common patients in India. All the stakeholders need to come together and brainstorm towards addressing this disparity for the benefit of the Indian population. To quote Madam Marie Curie, the discoverer of radioactivity and recipient of the Nobel prize, twice! – ‘I was taught that the way of progress was neither swift nor easy.’ There is a lot that we have achieved, and yet there are miles to go. Together, let us build a better future for the generation to come, with reforming healthcare for one and all.
(This article is authored by Dr. Baljinder Singh, Department of Nuclear Medicine and PET, Post Graduate Institute of Medical Education and Research (PGIMER)